Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal)

  • Technology appraisal
  • TA436
  • Published: 
Download guidance (PDF)

Advice

NICE is unable to make a recommendation about the use in the NHS of bevacizumab for treating epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer because no evidence submission was received from Roche for the technology.

  • National Institute for Health and Care Excellence (NICE)